TY - JOUR
T1 - Phenotypic and Molecular Epidemiology of ESBL-, AmpC-, and Carbapenemase-Producing Escherichia coli in Northern and Eastern Europe
AU - Sepp, Epp
AU - Andreson, Reidar
AU - Balode, Arta
AU - Bilozor, Anastasia
AU - Brauer, Age
AU - Egorova, Svetlana
AU - Huik, Kristi
AU - Ivanova, Marina
AU - Kaftyreva, Lidia
AU - Kõljalg, Siiri
AU - Kõressaar, Triinu
AU - Makarova, Maria
AU - Miciuleviciene, Jolanta
AU - Pai, Kristiine
AU - Remm, Maido
AU - Rööp, Tiiu
AU - Naaber, Paul
N1 - Funding Information:
We thank the Swedish Institute for Communicable Disease Control for laboratory assistance. We also thank all the clinical microbiology laboratories for their contribution of isolates and data, and Irja Roots for their technical assistance. The final version of our report was prepared for us by BioMedES United Kingdom (www.biomedes.biz). Funding. This study was financially supported by the European Union through the European Regional Development Fund (Grant SFOS reg. no. 3.2.0701.11-0013 ARMMD and Grant No. 2014-2020.4.01.15-0012), Estonian Research Council (Grant Nos. IUT34-19, IUT34-11, and IUT34-24), Estonian Ministry of Education and Research (Grant No. KOGU-HUMB), Baltic Antibiotic Resistance collaborative Network (BARN) subproject Baltic ESBL Epidemiology Project (BEEP).
Funding Information:
This study was financially supported by the European Union through the European Regional Development Fund (Grant SFOS reg. no. 3.2.0701.11-0013 ARMMD and Grant No. 2014-2020.4.01.15-0012), Estonian Research Council (Grant Nos. IUT34-19, IUT34-11, and IUT34-24), Estonian Ministry of Education and Research (Grant No. KOGU-HUMB), Baltic Antibiotic Resistance collaborative Network (BARN) subproject Baltic ESBL Epidemiology Project (BEEP).
Publisher Copyright:
© Copyright © 2019 Sepp, Andreson, Balode, Bilozor, Brauer, Egorova, Huik, Ivanova, Kaftyreva, Kõljalg, Kõressaar, Makarova, Miciuleviciene, Pai, Remm, Rööp and Naaber.
PY - 2019/11/22
Y1 - 2019/11/22
N2 - Extended-spectrum beta-lactamases (ESBL) and AmpC producing-Escherichia coli have spread worldwide, but data about ESBL-producing-E. coli in the Northern and Eastern regions of Europe is scant. The aim of this study has been to describe the phenotypical and molecular epidemiology of different ESBL/AmpC/Carbapenemases genes in E. coli strains isolated from the Baltic States (Estonia, Latvia, and Lithuania), Norway and St. Petersburg (Russia), and to determine the predominant multilocus sequence type and single nucleotide polymorphisms diversity of E. coli isolates deduced by whole genome sequencing (WGS). A total of 10,780 clinical E. coli strains were screened for reduced sensitivity to third-generation cephalosporins. They were collected from 21 hospitals located in Estonia, Latvia, Lithuania, Norway and St. Petersburg during a 5 month period in 2012. The overall prevalence of ESBL/AmpC strains was 4.7% by phenotypical test and 3.9% by sequencing. We found more strains with the ESBL/AmpC phenotype and genotype in St. Petersburg and Latvia than other countries. Of phenotypic E. coli strains, 85% contained confirmed ESBL genes (including blaCTX–M, blaTEM–29, blaTEM–71), AmpC genes (blaCMY–59, blaACT–12/–15/–20, blaESC–6, blaFEC–1, blaDHA–1), or carbapenemase genes (blaNDM–1). blaCTX–M–1, blaCTX–M–14 and blaCTX–M–15 were found in all countries, but blaCTX–M–15 prevalence was higher in Latvia than in St. Petersburg (Russia), Estonia, Norway and Lithuania. The dominating AmpC genes were blaCMY–59 in the Baltic States and Norway, and blaDHA–1 in St. Petersburg. E. coli strains belonged to 83 different sequence types, of which the most prevalent was ST131 (40%). In conclusion, we generally found low ESBL/AmpC/Carbapenemase prevalence in E. coli strains isolated in Northern/Eastern Europe. However, several inter-country differences in distribution of particular genes and multilocus sequence types were found.
AB - Extended-spectrum beta-lactamases (ESBL) and AmpC producing-Escherichia coli have spread worldwide, but data about ESBL-producing-E. coli in the Northern and Eastern regions of Europe is scant. The aim of this study has been to describe the phenotypical and molecular epidemiology of different ESBL/AmpC/Carbapenemases genes in E. coli strains isolated from the Baltic States (Estonia, Latvia, and Lithuania), Norway and St. Petersburg (Russia), and to determine the predominant multilocus sequence type and single nucleotide polymorphisms diversity of E. coli isolates deduced by whole genome sequencing (WGS). A total of 10,780 clinical E. coli strains were screened for reduced sensitivity to third-generation cephalosporins. They were collected from 21 hospitals located in Estonia, Latvia, Lithuania, Norway and St. Petersburg during a 5 month period in 2012. The overall prevalence of ESBL/AmpC strains was 4.7% by phenotypical test and 3.9% by sequencing. We found more strains with the ESBL/AmpC phenotype and genotype in St. Petersburg and Latvia than other countries. Of phenotypic E. coli strains, 85% contained confirmed ESBL genes (including blaCTX–M, blaTEM–29, blaTEM–71), AmpC genes (blaCMY–59, blaACT–12/–15/–20, blaESC–6, blaFEC–1, blaDHA–1), or carbapenemase genes (blaNDM–1). blaCTX–M–1, blaCTX–M–14 and blaCTX–M–15 were found in all countries, but blaCTX–M–15 prevalence was higher in Latvia than in St. Petersburg (Russia), Estonia, Norway and Lithuania. The dominating AmpC genes were blaCMY–59 in the Baltic States and Norway, and blaDHA–1 in St. Petersburg. E. coli strains belonged to 83 different sequence types, of which the most prevalent was ST131 (40%). In conclusion, we generally found low ESBL/AmpC/Carbapenemase prevalence in E. coli strains isolated in Northern/Eastern Europe. However, several inter-country differences in distribution of particular genes and multilocus sequence types were found.
KW - ESBL/AmpC/Carbapenemase genes epidemiology
KW - Escherichia coli
KW - multilocus sequence typing
KW - Northern and Eastern Europe
KW - whole genome sequencing
UR - http://www.scopus.com/inward/record.url?scp=85076715220&partnerID=8YFLogxK
U2 - 10.3389/fmicb.2019.02465
DO - 10.3389/fmicb.2019.02465
M3 - Article
AN - SCOPUS:85076715220
SN - 1664-302X
VL - 10
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
M1 - 2465
ER -